688553 Stock Overview
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor and injection drugs in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Sichuan Huiyu Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.05 |
| 52 Week High | CN¥17.12 |
| 52 Week Low | CN¥9.45 |
| Beta | 0.43 |
| 1 Month Change | -4.54% |
| 3 Month Change | 6.70% |
| 1 Year Change | -21.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.05% |
Recent News & Updates
Shareholder Returns
| 688553 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 7.3% | 4.9% | 2.1% |
| 1Y | -21.1% | -13.4% | -14.2% |
Return vs Industry: 688553 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.
Return vs Market: 688553 underperformed the CN Market which returned -14.2% over the past year.
Price Volatility
| 688553 volatility | |
|---|---|
| 688553 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688553 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688553's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,669 | Zhao Ding | www.huiyupharma.com |
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor and injection drugs in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, sodium valproate concentrated solution, epirubicin hydrochloride, fulvestrant, milrinone, fluorouracil, sodium thiosulfate, zoledronic acid, zoledronic acid concentrated solution, cisatracurium besylate, bortezomib, octreotide acetate, doxorubicin, and palonosetron hydrochloride. Sichuan Huiyu Pharmaceutical Co., Ltd.
Sichuan Huiyu Pharmaceutical Co., Ltd. Fundamentals Summary
| 688553 fundamental statistics | |
|---|---|
| Market cap | CN¥5.53b |
| Earnings (TTM) | CN¥133.69m |
| Revenue (TTM) | CN¥927.08m |
41.3x
P/E Ratio6.0x
P/S RatioIs 688553 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688553 income statement (TTM) | |
|---|---|
| Revenue | CN¥927.08m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥927.08m |
| Other Expenses | CN¥793.39m |
| Earnings | CN¥133.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 100.00% |
| Net Profit Margin | 14.42% |
| Debt/Equity Ratio | 5.6% |
How did 688553 perform over the long term?
See historical performance and comparison